Skip to content

efficacy of of The Derma Co 5 percent Glycolic + 2 percent Kojic Pigmentation Corrector Ampoule Kit

A Clinical Study to Evaluate the Pigmentation Reduction Potential of The Derma Co 5 percent Glycolic plus 2 percent Kojic Pigmentation Corrector Ampoule Kit on Healthy Human Subjects - NIL

Status
Active, not recruiting
Phases
Phase 4
Study type
Observational
Source
CTRI
Registry ID
CTRI/2024/07/070642
Enrollment
32
Registered
2024-07-15
Start date
Unknown
Completion date
Unknown
Last updated
2024-07-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Intervention1: Test Product-The Derma Co 5% Glycolic + 2% Kojic Pigmentation Corrector Ampoule Kit: Dose: Apply whole ampule drop wise in outward direction. Duration- once a day, Route of administrati

Sponsors

Honasa Consumer Limited
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.Gender: Male or Female with age 18-50, with male:female (80:20) ratio with normal , oily (avoid acne and too much oily skin) and combination skin. 3 to 4 candidates with Sensitive skin. 2. Subjects willing to give written informed consent 3. Women of child bearing potential must have a negative urine pregnancy test prior to study entry. 4. Are free of any systemic or dermatologic disorder, which, in the opinion of the investigator, will interfere with the study results or increase the risk of adverse events. 5. Are willing to avoid prolonged exposure of the treatment area to ultraviolet radiation (natural or artificial) for the duration of the study. 6. Should be able to read and write (in English, Hindi or local language). 7. Having valid proof of identity and age.

Exclusion criteria

Exclusion criteria: 1. Pregnant or nursing mothers 2.Scars, excessive terminal hair or tattoo on the studied area 3.Hypersensitivity, allergy antecedent (to any cosmetic product, raw material or hair dye) 4.Any clinically significant systemic or cutaneous disease, which may interfere with study treatment or procedures 5.Subjects on any medical treatment either systemic or topical which may interfere with the performance of the study treatment (presently or in the past 1 month) 6.Subject in an exclusion period or participating in another food, cosmetic or therapeutic trial.

Design outcomes

Primary

MeasureTime frame
1. Change in Lightness 2. Change in melanin 3. Gloss by glossTimepoint: At 0min, 30min, 7Days

Secondary

MeasureTime frame
Not ApplicableTimepoint: Not Applicable

Countries

India

Contacts

Public ContactPuneet Mittal

CCFT Laboratories

puneetmittal@mgcts.org8937015757

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026